clodronic acid has been researched along with FMR1-Related Primary Ovarian Insufficiency in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blomqvist, C; Elomaa, I; Saarto, T; Taskinen, MR; Vehmanen, L | 1 |
| Blomqvist, C; Elomaa, I; Risteli, J; Risteli, L; Saarto, T; Vehmanen, L | 1 |
2 trial(s) available for clodronic acid and FMR1-Related Primary Ovarian Insufficiency
| Article | Year |
|---|---|
Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Cyclophosphamide; Female; Fluorouracil; Humans; Lipoproteins; Methotrexate; Middle Aged; Premenopause; Primary Ovarian Insufficiency; Receptors, Estrogen; Tamoxifen | 2004 |
Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.
Topics: Adult; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Middle Aged; Premenopause; Primary Ovarian Insufficiency | 2004 |